A summary of the results of selected large, randomized, clinical trials of CRT stratified by key patient characteristics is presented in Figure 4A (5). The guidelines for implantation of a CRT device from the American Heart Association (6) are summarized in Figure 4B , and are discussed later. Electrocardiographic criteria. A wide QRS complex is a marker of electrical dyssynchrony and, in the presence of an LBBB pattern, is the most powerful predictor of CRT response. All of the randomized controlled trials (RCTs) that have shown improvement in HF symptoms and survival using patients enrolled in CRT with a minimal QRS duration of 120 to 150 ms (3, 4, 7) . The wider the QRS complex, the greater the likelihood of response. There is interplay between the type of bundle branch block and the QRS duration, likely because a sufficiently wide right bundle branch block (RBBB) (>150 ms) reflects delay in both bundles, so that delay of the LV lateral wall activation is present, and CRT is thus effective. However, the presence of bifascicular block (RBBB with left anterior fascicular block) was not predictive of CRT response in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) (8) . Current guidelines require the presence of LBBB if the QRS complex is relatively narrow (120 to 149 ms) for a Class I indication for CRT (6) . CRT is not indicated when the QRS complex is <120 ms, as it may potentially cause harm (6, 9) . Women are more likely to benefit from CRT than men, particularly when the QRS duration is <150 ms (10 Several strategies have been developed and are emerging to enhance device therapy. Pump efficiency is addressed with multisite left ventricle pacing and, potentially, His-Purkinje recruitment. Hardware reduction and simplification include leadless pacemakers (single component and multicomponent), and future advances may eliminate the need for batteries, which deplete over time. (4, 13) . However, the majority of trial participants had symptomatic HF (NYHA functional class II to IV); hence, the evidence supporting CRT for these patients is much stronger (6) . Clinical scenarios that warrant special consideration are discussed later. Atrial fibrillation. Experience in randomized trials of CRT in patients with atrial fibrillation (AF) and with symptomatic HF, QRS complex $120 ms, and no other indication for pacing is limited. The MUSTIC (Multisite Stimulation in Cardiomyopathies) trial reported improvement in functional status in patients with both sinus rhythm and AF (14) . A meta-analysis of observational studies reported a greater mortality risk and a higher rate of CRT nonresponse in AF compared with sinus rhythm (15) . Current guidelines recommend CRT implantation in patients with AF, HF, 
CRT Implantation
Response to CRT is determined by a host of parameters, including patient symptoms, objective measurements of functional capacity, and cardiac function. Those who demonstrate improvement in these parameters are termed responders, with super-responders referring to a subgroup with near normalization of LV function. Patients who demonstrate stabilization of LV function without experiencing the progressive decline that is expected with heart failure are termed nonprogressors. A small proportion of patients may experience a rapid decline in LV function following CRT (negative LVEF #35%, and QRS complex $120 ms (6) . However, it is critical to control the ventricular response in AF to provide >99% BiV pacing (6) .
CRT in patients who require pacing for bradycardia. RV apical pacing induces electrical and mechanical dyssynchrony, and has been associated with an increased risk of HF, particularly when pacing is frequent (>40%) and LV systolic function is depressed (16) . In patients with atrioventricular (AV) block who require pacing, EF #50%, and NYHA functional class I to III HF, BiV pacing (with a defibrillator, if indicated) reduces the combined endpoint of mortality, intravenous therapy for HF, or reduction in LV end-systolic volume compared with RV-only pacing (17) . BiV pacing can reasonably be considered in patients who are anticipated to require a high percentage of ventricular pacing and have EF #50% with mild HF symptoms (17) . M e a s u r e m e n t o f m e c h a n i c a l d y s s y n c h r o n y f o r p a t i e n t s e l e c t i o n . Only patients with a QRS complex $120 ms were enrolled in initial CRT studies. 
(5). (B)
Indications for CRT for patients in sinus rhythm: guidelines from the American Heart Association/American College of Cardiology. Severity of heart failure symptoms, ejection fraction, cardiac rhythm, QRS morphology, and QRS duration are considered when selecting patients for CRT. Madhavan et al.
CARE-HF
Cardiac Pacing: Part 2 A s s e s s i n g L V c a p t u r e : i m p o r t a n c e o f t h e 1 2 -l e a d E C G . Poor LV lead performance due to dislodgement, As the pacing output is reduced to 4 V, there is a change in QRS to LV pacing morphology. This represents loss of anodal stimulation with capture at the cathode as the pacing output is reduced. Abbreviations as in Figures 1 and 3. Madhavan et al. If pacing occurs between an LV electrode (cathode) and RV ring electrode (anode), and myocardial stimulation occurs only at the RV anode, effective CRT is not delivered (Figure 7) . Anodal-only capture is corrected by adjusting the pacing output or configuration. P e r c e n t a g e B i V p a c i n g : e n s u r i n g c o n t i n u o u s C R T . The percentage of QRS complexes that are resynchronized (i.e., the CRT "dose") correlates with HF outcome and mortality. Hayes et al. (43) reported optimal improvement in survival with >98.4% BiV pacing; a goal of >95% is commonly used. In a large national registry, 40% and 11% of patients had <98% Optimization is not routinely performed. RM TECHNOLOGY. T r a n s t e l e p h o n i c m o n i t o r i n g . In contrast to RI and TTM, RM checks patient and device status on a daily basis (as opposed to every 3 months), is fully automatic, and can verify transmissions and generate alerts when they are absent.
Evidence suggests that this form of monitoring detects abnormalities sooner and may improve survival; new pacemakers either include this capability or will do so in the near future (50). (57, 58) .
LEADLESS PACING
Cardiac pacemakers are extremely effective for treating symptomatic bradycardia. However, the same system paradigm has been in use for the past whereas the TPS has integrated electrically inert nitinol tines that are used solely for fixation ( Figure 15 ).
In the initial trial experience for both systems, successful implantation occurred in over 95% of cases, with major complications in 4% to 6.5% of cases, perforation or effusion in 1.5% to 1.6% of cases, and adequate pacing measures at 6 months in 90% to 98.3%. (62, 63 The battery/transmitter unit detects the pacing stimulus from the coimplant, and an ultrasound pulse is sent to the receiver electrode, which converts the ultrasound energy to a pacing pulse. ICD ¼ implantable cardioverter-defibrillator; other abbreviations as in Figures 1 and 3 . 
